There are no virological or clinical benefits to giving double doses of the drug oseltamivir to patients with influenza, according to a study published online by bmj.com.
Researchers at the South East Asian Infectious Disease Clinical Research
There are no virological or clinical benefits to giving double doses of the drug oseltamivir to patients with influenza, according to a study published online by bmj.com.
Researchers at the South East Asian Infectious Disease Clinical Research Network studied 326 patients who received either standard dose oseltamivir (75 mg twice a day or children's equivalent) or double dose (150 mg twice a day or children's equivalent) for five days.
The researchers found no differences between the groups in virus levels, deaths or rates of adverse events between the different doses.